Google Ads healthcare policy: what gets disapproved and why
Google Ads healthcare policy disapproves or limits hospital ads mainly for prescription drug terms, experimental treatments, unreliable claims, editorial issues and health audiences. The cause is often the landing page or keywords rather than the ad text. Read the named policy, fix the source, appeal only with a reason, and run a pre-launch review with a clinical reviewer.
Google Ads healthcare policy is the reason most first campaigns from hospitals and clinics stall in the first fortnight. The ads go in, a few are marked “Disapproved” or “Eligible (limited)”, someone edits a word and resubmits, and the cycle repeats until the team decides Google “does not allow healthcare ads”. It does allow them. It just reviews them against more rules than most categories, and it reviews the keyword and the landing page as well as the ad.
This article is about the platform mechanics: which Google policies a hospital or doctor in India actually runs into, why, and how to fix and appeal. What an ad may say under Indian professional and advertising rules is a separate question, which I cover in what hospital ads can and cannot say under NMC and ASCI rules. The two overlap, and I touch on the Indian layer briefly below, but the angle here is Google’s review system. For the full picture of running search ads for doctors, start with the complete guide to Google Ads for doctors in India.
A standing caveat: policies change, and the pages I link are the source of truth on the day you read this. Nothing here is legal advice.
How Google reviews a healthcare ad
Every ad, asset and keyword goes through review when it is created or edited, and Google’s systems also look at the landing page. Most reviews finish within a business day. Editing an ad restarts its review, which is why a team that tweaks copy daily can keep ads permanently “Under review”.
The statuses you will see matter more than people realise:
- Eligible: the ad can serve everywhere you targeted.
- Eligible (limited): the ad can serve, but not everywhere or not to everyone, because a restricted policy applies. For health advertisers this often reflects limits on personalised advertising, not a problem with the words.
- Disapproved: the ad cannot serve at all until it is fixed or a successful appeal is made.
The disapproval label names the policy. Read that label before touching the copy. Half the fixes I have seen go wrong because someone rewrote the headline when the problem was a keyword, an image asset or a blog post linked from the landing page.
What Google Ads healthcare policy restricts in India
Google’s Healthcare and medicines policy is a family of sub-policies, each with country-specific rules. Several do not touch a typical hospital. These are the ones that do, read for an Indian provider:
| Policy area | What it means for a hospital or clinic in India |
|---|---|
| Restricted drug terms | Prescription drug names cannot be used promotionally in ads or on landing pages outside a few countries, and India is not one of them. Keywords using them need certification. |
| Online pharmacies and telemedicine | An in-house pharmacy or e-consult service that sells or prescribes medicines online needs certification before it can advertise. Prescription drugs still cannot be promoted. |
| Speculative and experimental treatments | Promotion of speculative or experimental medical treatments, and of cell or gene therapies, is prohibited outside a narrow US exception. Educational content is treated differently from promotion. |
| Prenatal sex determination | Not allowed in India in any form. Fertility and imaging services should check every asset for wording that could be read this way. |
| Unapproved substances | Products Google classes as unapproved or dangerous cannot be advertised anywhere, which catches some supplement and wellness offers sold through clinics. |
Most general hospitals and specialist clinics will live mainly in the first and third rows. The rest mostly matter for pharmacy, fertility, wellness and aesthetic businesses.
Prescription drug terms: the disapproval nobody expects
The restricted drug terms policy is the single most common reason I see hospital ads limited or disapproved, and it rarely comes from the ad text. It comes from three places:
- The landing page. A service page that names a specific drug used in treatment, or a “related articles” block linking to a blog post about a medicine.
- The keywords. Broad match terms, or terms added from the search terms report, that include a drug or brand of injectable.
- Automatically created assets. Text pulled from the landing page by automated features, which can bring a drug name into an ad you never wrote.
Aesthetic and weight-management clinics trip this constantly, because many of the injectables their patients search for are prescription drugs. Oncology, diabetes and endocrinology pages do too. The practical fix is to describe the service or the consultation, not the medicine, on any page that takes paid traffic, and to keep drug-specific educational content on pages that are not used as ad destinations.
Experimental and regenerative treatments
Clinics offering stem cell procedures, other cell-based therapies or treatments that are still being studied will find Google treats promotion of these as prohibited, not restricted. There is no certification route in India. Educational content is allowed, but an educational page that ends in a booking form is promotion by any sensible reading.
If your service line sits here, accept that search ads are largely closed and put the effort into content, referrals and your Google Business Profile. Trying to disguise the service with vague wording tends to end in repeated disapprovals and, eventually, account-level trouble.
The general policies healthcare trips most
Many healthcare disapprovals are not under the healthcare policy at all. They come from policies every advertiser faces, which medical copy happens to trigger more often:
- Misrepresentation, unreliable claims. Improbable results, guarantees, “100% success”, “permanent cure”. Google’s misrepresentation policy also treats exploiting illness to push urgency as clickbait.
- Misrepresentation, identity and qualifications. Omitting or blurring who is offering the service, or implying credentials a doctor does not hold.
- Editorial. A phone number typed into the ad text, gimmicky capitals (“FREE CONSULT”), repeated exclamation marks, or an ad that does not name the business.
- Destination requirements. Landing pages that do not load, redirect unexpectedly, or do not match what the ad offers.
- Sexual content. India is among the locations where Google does not serve sexual content at all, so sexual health services need careful, clinical wording in both ad and page.
For how to write copy that avoids these without going bland, see ad copy for doctors: compliant, specific, clickable.
Health and personalised advertising
The restriction that surprises marketers from other industries is on audiences. Under Google’s health in personalised advertising policy, advertisers promoting health products or services cannot use advertiser-curated audiences: Customer Match, your data segments, audience expansion and lookalike segments. The policy covers physical and mental health conditions, treatments, invasive procedures and more.
What remains available is Google’s predefined audiences (in-market, affinity, demographics and life events, with some exceptions) and location targeting. In practice, “Eligible (limited)” under this policy usually means an audience you attached is being ignored for the health ad, not that the ad is broken. Remove the audience rather than appealing.
India’s own data protection law adds a second, independent reason to be careful with patient lists. I cover that in privacy-safe remarketing in healthcare and, for consent, in consent under DPDP for hospital marketing.
The Indian law layer on top of Google
Passing Google review does not make an ad lawful in India, and a lawful ad can still be disapproved. Three touchpoints matter for search ads:
- The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. It restricts advertisements for drugs and remedies for certain purposes and for a schedule of diseases and conditions. The text of the Act on India Code is short and worth reading once. Copy that implies a remedy for a scheduled condition deserves legal review.
- The ASCI Code. ASCI’s code requires ads to be truthful and not misleading by implication or omission, and it has specific guidelines on awards and rankings in healthcare advertising and on qualifications for health influencers.
- NMC professional conduct. Doctors are bound by professional conduct rules on self-promotion and soliciting patients. The NMC’s 2023 Registered Medical Practitioner (Professional Conduct) Regulations were put in abeyance soon after notification, so check the current position with counsel before relying on either the 2002 or 2023 text.
This is not legal advice. The detail on what each rule means for ad content is in the NMC and ASCI article linked above.
Where each specialty usually runs into trouble
After enough audits, the disapprovals start to cluster by service line. This is the pattern I brief new teams on, so they know where to look first:
- Aesthetics and dermatology: injectable brand names in keywords and pages, before-and-after imagery, and “permanent” or “guaranteed” results.
- Weight management and diabetes: named medicines on landing pages, and outcome promises about kilos or sugar levels.
- Oncology: named therapies and drugs on treatment pages, and wording that could read as a cure claim under Indian rules as well as Google’s.
- Fertility and imaging: anything that could be read as prenatal sex determination, plus success-rate claims.
- Orthopaedics and pain: regenerative or cell-based procedures promoted on the same page as standard treatments.
- Urology and sexual health: the sexual content policy and restricted drug terms together, which calls for clinical, plain wording.
A simple habit catches most of these early. Before a landing page goes live, search its full text, including linked blocks and footers, for drug names and for words like cure, guarantee, permanent and success. It takes minutes and saves days of review cycles.
Fixing a disapproval, step by step
When an ad is disapproved, this is the sequence I ask teams to follow, in order:
- Read the named policy. Hover on the status and open the policy link. Note whether it is the ad, an asset, a keyword or the destination.
- Check the landing page first if the policy is about drugs, treatments or claims. Look at linked blocks, pop-ups and footers too.
- Check keywords and automated assets for drug names or claim language pulled from the page.
- Edit and save. Saving an edit triggers a fresh review; for many issues this is all that is needed.
- Appeal only with a reason. Google’s appeal flow offers “Dispute decision” if you believe the review was wrong, or “Made changes to comply with policy” after a fix. Each ad has a limited number of appeals, and Google asks advertisers to wait between them.
- Log it. Record the policy, the cause and the fix. The same cause will recur across units and agencies.
One firm rule: never try to route around a disapproval with a new account, a cloaked page or deliberately misspelt terms. Google treats that as circumventing its systems, and account suspension is a far bigger problem than one disapproved ad group.
A pre-launch policy review that prevents most of this
Most disapprovals are avoidable with a short review before launch. I run it as a checklist signed off by marketing and a clinical reviewer, with legal consulted on anything borderline:
- No prescription drug names in ads, keywords or any landing page receiving paid traffic.
- No experimental or cell-based treatment promoted on any destination.
- No outcome claims, guarantees, success rates or “best” without substantiation that ASCI would accept.
- No phone numbers in ad text; calls handled through call assets.
- No Customer Match or uploaded lists attached to health campaigns.
- Every landing page loads on mobile, names the provider and matches the ad.
- Clinical reviewer has seen every headline and description in the pool, not only the preview.
The printable version sits in the Google Ads launch checklist for doctors. Landing page decisions that affect review are covered in landing pages for doctor consultation ads, and the keyword side of drug and treatment terms is in keywords that book appointments vs keywords that waste budget.
Questions people ask
It is the set of Google advertising rules that decide which health-related ads can run, where, and with what targeting. The core is the Healthcare and medicines policy, which covers prescription drugs, pharmacies, experimental treatments and similar topics country by country. Around it sit general policies on misleading claims, editorial standards, landing pages and personalised advertising, all of which healthcare ads trigger more often than most categories.
Often the difference is in the landing page or targeting, not the ad. A page naming a prescription drug, a claim Google reads as unreliable, or a customer list attached to the campaign can limit or disapprove ads that look harmless. Competitors may also run fewer services, different pages, or simply have issues you cannot see. Ask your team for the named policy on each limited ad before assuming unfair treatment.
Yes. Hospitals, clinics and doctors can advertise consultations, procedures, diagnostics and health checks on Google in India. The restrictions are specific: prescription drug terms, online pharmacy and telemedicine certification, experimental treatments, prenatal sex determination and limits on personalised audiences. A hospital that describes services factually, uses clean landing pages and avoids customer lists for health campaigns can run search ads normally.
It means the ad can serve but with restrictions, for example in some locations, to some users, or without certain targeting. For health advertisers it frequently reflects the personalised advertising restriction, where an attached audience cannot be used. It is not a disapproval. Check which policy is named. If it is about audiences, remove the curated audience. If it is about content, review the ad and landing page.
Yes, educational content is valuable for patients and for search visibility. The issue is only whether those pages are used as ad destinations or linked prominently from pages that are. Keep drug-specific education on content pages, and keep paid landing pages focused on the service, the doctor and booking. Every page should still be clinically reviewed before publishing, whatever its role in advertising.
No. Google review checks Google’s policies, not Indian law or professional conduct rules. An ad can pass review and still raise questions under the Drugs and Magic Remedies Act, the ASCI Code or NMC conduct rules, and a lawful ad can still be disapproved by Google. Treat the two as separate gates with separate owners, and involve legal counsel on borderline claims. This is not legal advice.
Google says most ads are reviewed within one business day, with complex cases taking longer. Every edit restarts review, so frequent tweaking delays serving. Appeals are handled separately and there is a limit on appeals per ad, with Google asking advertisers to wait between attempts. Build a few days of buffer into any campaign launch that is tied to a date, such as a new doctor joining or a camp.
Most often prescription drug terms. Many injectables patients search for are prescription drugs, and naming them in keywords, ads or landing pages triggers the restricted drug terms policy in India. Describe the consultation and the category of treatment instead, move drug names off paid landing pages, and remove those terms from keywords. Before-and-after imagery and outcome claims create separate problems under misrepresentation and Indian advertising rules.
Not for campaigns promoting health services. Google’s health in personalised advertising policy stops health advertisers from using advertiser-curated audiences including Customer Match, your data segments and lookalikes. Separately, India’s DPDP framework requires a clear purpose and valid consent for using personal data. For health campaigns, rely on keywords, locations and Google’s predefined audiences instead, and involve your privacy lead in any use of patient contact data.
A list of disapproved and limited ads or assets, the named policy for each, the cause found, the fix made and whether an appeal was filed. Also any warnings at account level. This log is more useful than a clean dashboard because it shows whether the same mistakes recur. If an agency cannot produce it, they are probably not reading policy notices carefully, and that risk eventually reaches the account.
No. Opening a new account to escape disapprovals or warnings can be treated by Google as circumventing its systems, which can lead to suspension of all linked accounts. Fix the underlying pages, keywords and copy instead, and appeal where you genuinely believe a decision is wrong. A clean history on one well-owned account is worth far more than a fresh start that carries the same problems forward.
At least two people: a marketing owner who checks Google policy and brand standards, and a clinical reviewer who checks every medical statement for accuracy. Legal or compliance should see anything involving claims, pricing, offers or regulated services. The clinical reviewer needs the full pool of headlines and descriptions, not a single preview, because Google assembles combinations automatically and some may read differently in context.
Centralise the rules and decentralise the facts. A central team owns the policy checklist, the approved claim library, landing page templates and the disapproval log. Units supply doctor availability, languages and local details. New campaigns go through the same pre-launch review whichever unit or agency builds them. Shared negative lists that exclude drug and experimental treatment terms also prevent the most common disapprovals at source.
Read my takes first in Google Search
